F11C ANTIGEN - A MEMBRANE MARKER ABLE TO DISTINGUISH 2 REGRESSIVE AND PROGRESSIVE VARIANTS FROM A RAT COLON ADENOCARCINOMA

被引:12
作者
CAIGNARD, A
GENNE, P
OLSSON, NO
ORIOL, R
MARTIN, F
机构
[1] FAC MED DIJON,IMMUNOL LAB,INSERM,U252,7 BD JEANNE ARC,F-21033 DIJON,FRANCE
[2] FAC PHARM CHATENAY MALABRY,CNRS,URA 622,F-92296 CHATENAY MALABRY,FRANCE
关键词
D O I
10.1002/ijc.2910460414
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Cell variants that differ in their tumorigenicity and immunogenicity have been isolated from a BDIX rat colon adenocarcinoma cell line, DHD/K12. One variant, PRO, and the clones derived from it, are poorly immunogenic and induce progressive and metastatic tumors; the other one, REG, and its clones, are highly immunogenic and induce regressive tumors. When looking for a membrane marker distinguishing between PRO and REG lines, we obtained monoclonal hybridomas by immunizing BALB/c mice with PROb or REGb cell clones. Hybridoma FI IC, producing an IgM monoclonal antibody (MAb) was able to distinguish between the cell variants on membrane immunofluorescence. All REGb cells strongly express FI IC membrane antigen. On PROb cells, FI IC antigen expression is weak, as demonstrated by cytofluorimetric analysis, and limited to a fraction of the cell population. The FI IC membrane antigen is highly specific for the DHD/K12 cell line and the variants derived from it, but is not expressed on cells dissociated from the DHD transplanted tumor, from which DHD/K12 was established, suggesting that FI IC antigen emerged during cell culture. Fluorescence absorption on synthetic oligosaccharides demonstrated that FI IC antibody cross‐reacts with A type 3, A type 4 and A type 5 chain blood group tetrasaccharides. Copyright © 1990 Wiley‐Liss, Inc., A Wiley Company
引用
收藏
页码:633 / 639
页数:7
相关论文
共 33 条
[1]  
ABE K, 1984, J IMMUNOL, V132, P1951
[2]   BLOOD-GROUP-RELATED ANTIGENS IN COLONIC CARCINOGENESIS [J].
BARA, J ;
DECAENS, C .
ANNALES DE L INSTITUT PASTEUR-IMMUNOLOGY, 1987, 138 (06) :891-899
[3]   TUM- VARIANTS - IMMUNOGENIC VARIANTS OBTAINED BY MUTAGEN TREATMENT OF TUMOR-CELLS [J].
BOON, T .
IMMUNOLOGY TODAY, 1985, 6 (10) :307-311
[4]   REJECTION BY SYNGENEIC MICE OF CELL VARIANTS OBTAINED BY MUTAGENESIS OF A MALIGNANT TERATOCARCINOMA CELL LINE [J].
BOON, T ;
KELLERMANN, O .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1977, 74 (01) :272-275
[5]   INTERACTION BETWEEN 2 CELLULAR SUBPOPULATIONS OF A RAT COLONIC-CARCINOMA WHEN INOCULATED TO THE SYNGENEIC HOST [J].
CAIGNARD, A ;
MARTIN, MS ;
MICHEL, MF ;
MARTIN, F .
INTERNATIONAL JOURNAL OF CANCER, 1985, 36 (02) :273-279
[6]   SPECIFICITY OF THE IMMUNE-RESPONSE LEADING TO PROTECTION OR ENHANCEMENT BY REGRESSIVE AND PROGRESSIVE VARIANTS OF A RAT COLON-CARCINOMA [J].
CAIGNARD, A ;
PELLETIER, H ;
MARTIN, F .
INTERNATIONAL JOURNAL OF CANCER, 1988, 42 (06) :883-886
[7]  
CHEN HT, 1985, J BIOL CHEM, V260, P3208
[8]   INSITU DETECTION OF MYCOPLASMA CONTAMINATION IN CELL-CULTURES BY FLUORESCENT HOECHST-33258 STAIN [J].
CHEN, TR .
EXPERIMENTAL CELL RESEARCH, 1977, 104 (02) :255-262
[9]  
CHIBA I, 1987, CANCER RES, V47, P1815
[10]  
CHIBA I, 1989, CANCER RES, V49, P3972